Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of RU 486, a synthetic steroid that is a powerful antagonist of glucocorticoid hormones, was tested on the transcription of several glucocorticoid-regulated genes in different cell types: inflammatory murine macrophages and two human mammary gland-derived cell lines, MDA-MB-231 and HBL-100. The transcription of genes which are positively regulated by glucocorticoids (e.g., tissue-type plasminogen activator and c-myc in mammary cells, c-fos in macrophages) and that of genes which are negatively regulated by these agents (e.g., urokinase-type plasminogen activator in all three cell types, TNF-a and IL-1 in macrophages) was explored. RU 486 almost completely prevented the effects of dexamethasone on the transcription of these various genes. When added alone, RU 486 had essentially no agonist activity.
 ...
PMID:Antagonist effect of RU 486 on transcription of glucocorticoid-regulated genes. 312 70

Harvest fluid concentrates (HFC's) from three human mammary tumor cell lines (T47D), HSO578T, and MDA-MB-157), one nontumorigenic human mammary cell line (HBL-100), and one mouse mammary tumor cell line (MCG-T14) stimulated thymidine incorporation in confluent quiescent BALB/c 3T3 cells in a dose-dependent manner. HFC's from all of the cell lines also exhibited plasminogen activator activity. Levels of mitogenic activity and plasminogen activator in the HFC preparations were not correlated with cell growth potential or with the amount of protein which was recovered in the HFC's. High levels of mitogenic activity and plasminogen activator in the HFC's from HBL-100 cells suggested that the production of these biological activities is not a unique feature of tumorigenic mammary cells. The HFC's from three human cell lines (T47D), HS0578T, MDA-MB-157) exhibited high levels of mitogenic activity but low levels of plasminogen activator. This suggested that plasminogen activator is not the source of the mitogenic activity in the HFC's from these cells. The HFC's from a human mammary carcinoma line, BT-20, contained very low levels of mitogenic activity and plasminogen activator. In addition, BT-20 HFC's inhibited the mitogenic activity of fetal bovine serum in a dose-dependent manner. It is proposed that BT-20 cells are the source of a macromolecular inhibitor of serum mitogens.
 ...
PMID:Mitogenic activity and plasminogen activator in harvest fluid concentrates from mammary cells in culture. 719 75

We report three Japanese patients with psoriasis vulgaris associated with nonalcoholic fatty liver disease in which the skin lesions dramatically resolved after treatment of the fatty liver disease with ursodeoxycholic acid (UDCA). According to the literature, arachidonic acid is released from phospholipid by phospholipase A(2) (PLA(2)) and is a precursor of eicosanoids, including prostaglandins, leucotrienes, and thromboxanes, which are potent inflammatory mediators. PLA(2) activity has been reported to be significantly raised in the serum and skin tissue of patients with psoriasis. UDCA has been reported to suppress the increased activity of group IIA PLA(2), a secretory low-molecular-weight PLA(2) (PLA(2)IIA), in HepG2 cells (a human hepatoblastoma-derived cell line) and in gallbladder and gallbladder bile samples from patients with cholesterol stones. Thus, UCDA may improve the skin lesions of patients with psoriasis by suppressing PLA(2)IIA activity.
 ...
PMID:Psoriasis treated with ursodeoxycholic acid: three case reports. 1737 9